RNA binding motif protein 28Genealiases: ANES · NOP4
Q-omics provides the consensus-scored RBM28 profile across patient tissues and cancer cell-line models. RBM28 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RBM28 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RBM28 protein abundance shows 26,985 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, HNSC, and LUAD as cancer lineages where RBM28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM28 survival associations across molecular data types. RBM28 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM28 RNA expression–survival associations across cancer types. High RBM28 expression shows unfavorable associations in LIHC, KICH, MESO, KIRC, CESC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RBM28 RNA expression.
This table summarizes RBM28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM28 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, BLCA, STAD and LIHC. The HNSC box plot shows higher RBM28 RNA expression in tumor versus normal tissue (log2 FC = +0.992, t-test p < 0.001).
This table shows molecular features associated with RBM28 in patient tissues and cancer cell lines. In patient samples, RBM28 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
